Yes, Illumina, Inc., a dominant global leader in DNA sequencing and genetic testing systems, implemented significant workforce reductions and corporate restructuring initiatives as part of a strategic effort to streamline operations, reduce operating expenses, and improve profitability. Driven by cost-saving mandates, shifting macroeconomic pressures, and activist investor oversight, the company executed layoffs across various global departments while refocusing its core product development and molecular diagnostics pipelines to optimize long-term operational efficiency.